Minerva Neurosciences (NERV) vs NRX Pharmaceuticals (NRXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed NRX Pharmaceuticals (NRXP) over the past year, losing 5.6% versus a loss of 18.2%. Over five years, NERV leads with a -76.9% price change compared with -97.4% for NRXP. NRX Pharmaceuticals is the larger company by market cap ($112.6 million vs $112.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NERV | NRXP |
|---|---|---|
| Share price | $2.35 | $2.60 |
| Market cap | $112.21M | $112.57M |
| 1-day change | -2.89% | -4.06% |
| YTD return | -41.54% | -4.06% |
| 1-year return | -5.62% | -18.24% |
| 5-year return | -76.87% | -97.37% |
| EPS (TTM) | $-36.12 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.23M |
| Net income (latest FY) | $-293.42M | $-28.62M |
| Gross margin | — | 58.78% |
| Operating margin | — | -1324.41% |
| Net margin | — | -2336.49% |
| 52-week high | $12.46 | $5.06 |
| 52-week low | $2.28 | $1.62 |
| Distance from 52-week high | -81.14% | -48.57% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +339.57% | +1380.77% |
| Average volume | 181.64K | 860.32K |
| Shares outstanding | 47.75M | 43.30M |
| Employees | 7 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NERV has outperformed NRXP by 12.6 percentage points over the past year.
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About NRX Pharmaceuticals
NRXP stock →NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
NERV vs NRXP FAQ
Which is bigger, Minerva Neurosciences or NRX Pharmaceuticals?
NRX Pharmaceuticals (NRXP) is larger, with a market capitalization of $112.57M compared with $112.21M for Minerva Neurosciences (NERV).
Which stock has performed better over the past year, NERV or NRXP?
NERV returned -5.62% over the past 12 months, compared with -18.24% for NRXP (price return, excluding dividends). Past performance does not predict future results.
Are Minerva Neurosciences and NRX Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.